RT Journal Article SR Electronic T1 Preclinical Efficacy of the c-Met Inhibitor CE-355621 in a U87 MG Mouse Xenograft Model Evaluated by 18F-FDG Small-Animal PET JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 129 OP 134 DO 10.2967/jnumed.106.038836 VO 49 IS 1 A1 Jeffrey R. Tseng A1 Keon Wook Kang A1 Mangal Dandekar A1 Shahriar Yaghoubi A1 Joseph H. Lee A1 James G. Christensen A1 Stephen Muir A1 Patrick W. Vincent A1 Neil R. Michaud A1 Sanjiv S. Gambhir YR 2008 UL http://jnm.snmjournals.org/content/49/1/129.abstract AB The purpose of this study was to evaluate the efficacy of CE-355621, a novel antibody against c-Met, in a subcutaneous U87 MG xenograft mouse model using 18F-FDG small-animal PET. Methods: CE-355621 or control vehicle was administered intraperitoneally into nude mice (drug-treated group, n = 12; control group, n = 14) with U87 MG subcutaneous tumor xenografts. Drug efficacy was evaluated over 2 wk using 18F-FDG small-animal PET and compared with tumor volume growth curves. Results: The maximum %ID/g (percentage injected dose per gram of tissue) of 18F-FDG accumulation in mice treated with CE-355621 remained essentially unchanged over 2 wk, whereas the %ID/g of the control tumors increased 66% compared with the baseline. Significant inhibition of 18F-FDG accumulation was seen 3 d after drug treatment, which was earlier than the inhibition of tumor volume growth seen at 7 d after drug treatment. Conclusion: CE-355621 is an efficacious novel antineoplastic chemotherapeutic agent that inhibits 18F-FDG accumulation earlier than tumor volume changes in a mouse xenograft model. These results support the use of 18F-FDG PET to assess early tumor response for CE-355621.